Research

*September 2024* Symptom progression was significantly delayed when patients with EGFR-mutated non–small cell lung cancer (NSCLC) were treated with amivantamab-vmjw (Rybrevant) plus lazertinib (Lazcluze) compared with osimertinib (Tagrisso) monotherapy, according to a presentation from the 2024 IASLC World Conference on Lung Cancer (WCLC).1 The study assessed the results observed in the phase…

*September 2024* Early efficacy and safety were reported with firmonertinib (AST2818; formerly furmonertinib) in those with non–small cell lung cancer (NSCLC) harboring EGFR P-loop and αC-helix compressing (PACC) mutations, according to findings from the phase 1b FURHTER trial presented at the IASLC 2024 World Conference on Lung Cancer (WCLC). “Firmonertinib has shown promising…

*September 2024* In this video, panelists discuss how the SKIPPirr data outcomes presented at World Conference for Lung Cancer 2024 provide valuable insights into the potential use of amivantamab for advancing lung cancer treatment strategies. Watch here.

*September 2024* In this video, Prof Ignacio Gil-Bazo (Catholic University of Valencia, Valencia, Spain), Dr Mariana Brandão (Institut Jules Bordet, Brussels, Belgium), Prof Benjamin Besse (Institut Gustave Roussy, Villejuif, France), and Prof Enriqueta Felip (Vall d'Hebron University Hospital, Barcelona, Spain) discuss the latest developments in treating EGFR mutated NSCLC, with…

*October 2024* In this video update, Dr Herbert H. Loong shares his perspective on the latest data on oncogene-addicted non-small cell lung cancer (NSCLC) to emerge from two important congresses, WCLC and ESMO 2024. Dr Loong reviews data from the following clinical trials (with corresponding video time stamps): 0:13 - TRUST-II…

*September 2024* The FDA has approved amivantamab-vmjw (Rybrevant) in combination with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) harboring EGFR exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR TKI.1 The regulatory…

*September 2024* Osimertinib is now an FDA-approved therapy for stage III NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations that did not progress during or following platinum-based chemoradiation. The FDA approved osimertinib (Tagrisso) for the treatment of patients with stage III EGFR-mutated non–small cell lung cancer (NSCLC) whose…

*September 2024* Monday, September 23, 2024, Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) reported initial Phase 2 data of BDTX-1535. The data demonstrated encouraging clinical responses and durability of BDTX-1535 in patients with relapsed/refractory epidermal growth factor receptor (EGFR)-mutant (EGFRm) non-small cell lung cancer (NSCLC). “Patients often become resistant to osimertinib with the emergence of…

*September 2024* The investigational HER​​3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) elicited a statistically significant improvement in progression-free survival (PFS) vs platinum-based chemotherapy in patients with locally advanced or metastatic EGFR-mutated non–small cell lung cancer (NSCLC) who were previously exposed to an EGFR TKI, meeting the primary end point of the…

*August 2024* "You're only as old as you feel." Back in 2021, German researchers gave some weight to that expression with a longitudinal study suggesting that feeling "younger" protects middle-age and older adults against damaging stress. Lung cancer is generally viewed as an older person's disease, with an average age…